Efficacy and safety of dapsone in adult primary immune thrombocytopenia.
Marion Larue, Guillaume Moulis, Manuela Rueter...
https://pubmed.ncbi.nlm.nih.gov/39874521Actively Recruiting
Age: 18Years +
All Genders
ID02877706
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Led by University Hospital, Toulouse · Updated on 2025-12-31
1500
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting information from adults newly diagnosed with Immune Thrombocytopenia (ITP) or Autoimmune Hemolytic Anemia (AIHA) in France to better understand these conditions. This registry tracks clinical features and looks at how treatments are used in real-world settings, including how well patients follow treatment guidelines. The study is observational and does not involve specific treatments but focuses on gathering data over time. Participants are adults with recent diagnoses of ITP or AIHA or who have just started a related medication called Fosfamatinib. Since this is a registry, there are no assigned treatment groups or interventions. The study collects ongoing information on patients' health events, treatment responses, and any side effects they may experience, aiming to assess treatment risks and benefits in everyday medical practice. During the study, researchers gather data at the start and throughout follow-up visits up to 15 years. They monitor how the diseases progress, treatment lines, adherence to management guidelines, and any adverse drug reactions or bleeding events. This long-term observation helps provide a comprehensive view of these conditions and their management in adults. Participation duration can extend up to 15 years depending on follow-up.
CONDITIONS
Brief Title
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Newly diagnosed with Immune Thrombocytopenia (ITP) or Autoimmune Hemolytic Anemia (AIHA)
- Initiation of Fosfamatinib treatment
You will not qualify if you...
- Opposition to data collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 15 years
Participants who undergo routine care are observed to track the natural evolution of their condition and treatment outcomes.
Regular follow-up visits over 15 years
Trial Site Locations
Total: 1 location
1
Service de Médecine Interne
Toulouse, France, 31000
Actively Recruiting
Loading map...
Research Team
M
Moulis Guillaume, MD PhD
J
Johanne Germain, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here